Status:
COMPLETED
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to: * To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained...
Detailed Description
Participants with schizophrenia or schizoaffective disorder who are competent to participate in the informed consent process and provide written informed consent will be enrolled into the study. Parti...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of either schizophrenia or schizoaffective disorder.
- Caucasian or Non-Caucasian.
- Subjects will be currently treated with one of the new generation antipsychotics: olanzapine, risperidone, quetiapine, or ziprasidone.
- Subjects will meet a prior criteria for cognitive impairment severity. The RBANS will be used to determine the level of cognitive impairment.
Exclusion
- History of an organic brain disease.
- History of DSM-IV alcohol or substance abuse (within the last month), or DSM-IV alcohol or substance dependence (within the last six months).
- Pregnant women.
- Uncontrolled hypertension defined as high blood pressure exceeding 140/90 on three consecutive readings despite adequate treatment.
- Subjects receiving venlafaxine.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00161031
Start Date
April 1 2004
End Date
December 1 2006
Last Update
August 19 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Veterans Affairs Maryland Health Care System
Baltimore, Maryland, United States, 21228
2
Maryland Psychiatric Research Center
Catonsville, Maryland, United States, 21228